Qomel Company Limited (9600) Fair Value & Analysis
Healthcare · SA · Market cap 336M SAR
Fair value as of: Aug 15, 2026
From 16 valuation models · updated 2 days ago
Fair value updated Aug 15, 2026, revised from 36.33 SAR to 49.61 SAR (+36.6%) since Aug 1, 2026. Share price −7.0% over the past month.
Below-average quality, screening 11% undervalued on our models.
What matters now
- Our model range runs from 36.58 SAR (bear) to 62.64 SAR (bull), base 49.61 SAR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 28/100 (below-average quality) with high evidence: the data supports the verdict.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 15, 2026.
How to read this chart
27‑month range 36.75 SAR – 67.50 SAR · fair‑value band 36.58 SAR – 62.64 SAR · the 44.62 SAR price screens below the 49.61 SAR fair value. Dashed = 300-day average. As of Aug 15, 2026.
Analysis
Qomel Company Limited (9600) currently trades at 44.62 SAR, while our model-based Fair Value estimate is 49.61 SAR, implying the stock looks roughly 11.2% undervalued today. The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Qomel Company Limited generated revenue of 132M SAR at a net margin of 11.3%. Revenue declined 7.1% year over year. It earns a return on equity of 13.3%. Net debt stands at 17.7M SAR. Fundamentals as of Aug 15, 2026
Our scenario range runs from 36.58 SAR (bear case) to 62.64 SAR (bull case); at 44.62 SAR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 11%, 9600 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (61.65 SAR) versus Dividend Discount (8.50 SAR). Highest evidence: Residual Income (76).
Notify me when 9600 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 33 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Qomel Company Limited operates as a healthcare company in Saudi Arabia. The company is involved in the sale of medicine and natural medicinal herbs. It also offers pharmaceutical and medical supplies services. The company was founded in 2007 and is headquartered in Riyadh, Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Qomel Company Limited reported revenue of 132M SAR in FY2025 versus 61.2M SAR in FY2021, a compound +21.2%/yr. Reported net income was 15.0M SAR in FY2025, compounding +25.0%/yr from FY2021.
Watch 9600: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 63 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | -14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.33 | HK$2.04 | -39% |
| Raia Drogasil S.A RADL3 | R$18.00 | R$15.58 | -13% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 726.02 MXN | +57% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | -21% |
| MedPlus Health Services Limited MEDPLUS | ₹675.05 | ₹379.25 | -44% |
| Yixintang Pharmaceutical Group 002727 | ¥12.29 | ¥9.45 | -23% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.51 | ¥10.05 | -39% |
Compare Qomel Company Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Qomel Company Limited (9600) overvalued or undervalued?
What is the fair value of 9600?
What is the quality score of 9600?
What is the revenue of Qomel Company Limited (9600)?
What is the net profit margin of 9600?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Qomel Company Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.